Cantitate/Preț
Produs
Total produse
Vezi coșul
Enzyme Action de Stein

Enzyme Action

Autor Stein
en Limba Engleză Hardback – 13 iul 2011
Few scientists have the knowledge to perform the studies that are necessary to discover and characterize enzyme inhibitors, despite the vested interest the pharmaceutical industry has in this field. Beginning with the most basic principles pertaining to simple, one-substrate enzyme reactions and their inhibitors, and progressing to a thorough treatment of two-substrate enzymes, Kinetics of Enzyme Action: Essential Principles for Drug Hunters provides biochemists, medicinal chemists, and pharmaceutical scientists with numerous case study examples to outline the tools and techniques necessary to perform, understand, and interpret detailed kinetic studies for drug discovery.
Citește tot Restrânge

Preț: 66167 lei

Preț vechi: 71921 lei
-8%

Puncte Express: 993

Carte tipărită la comandă

Livrare economică 30 septembrie-14 octombrie

Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă

Specificații

ISBN-13: 9780470414118
ISBN-10: 0470414111
Pagini: 320
Dimensiuni: 161 x 240 x 22 mm
Greutate: 0.64 kg
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Medicinal chemists who need to understand basic principles of enzyme kinetics so they are better able to interpret SAR data, scientists, senior scientists and directors in screening and biochemistry departments of biotech and pharmaceutical companies, biochemists, enzymologists, and molecular biologists, graduate students in medicinal chemistry, enzymology, metabolism and pharmacology, and pharma / drug related programs.

Notă biografică

ROSS L. STEIN received his PhD in physical organic chemistry from Indiana University in 1978, after which he conducted post-doctoral research in mechanistic enzymology at the University of Kansas. His career has included positions at Merck, where he headed the Enzymology Department, and ProScript (acquired by Millennium in 1999) as vice president of biochemistry. At ProScript, Dr. Stein was instrumental in the pre-clinical development and co-inventor of the drug VELCADETM, a proteasome inhibitor used to treat multiple myeloma. In 2001, he accepted a position at Harvard Medical School to establish and head the Laboratory for Drug Discovery in Neurodegeneration. Most recently, from 2009-2011, Dr. Stein was vice president of drug discovery at Sirtris Pharmaceuticals.

Descriere

Few scientists have the knowledge to perform the studies that are necessary to discover and characterize enzyme inhibitors, despite the vested interest the pharmaceutical industry has in this field.